Ann: Positive Regulatory Updates, page-29

Albert- whilst I don't agree with Abdi that this is a scam, it's still one of the funniest things I've read on this forum and it did serve the purpose of nicely chronicling some of the completely over the top (and un-fulfilled) predictions made over time about this stock. There does seem to be a group of cheerleaders here who, despite limited understanding of the data, disease, clinical trials or regulations appear simplistically to view this as some kind of SRX Mk2- and hence we keep reading unscientific and ill-informed claims like the panco trial shows device is " life-saving' (nonsense, NO it's not- any survival advantage is totally unproven at this point) or that it's all BSI's fault because they "set the trial protocol and the dose" (err- NO they don't) . In my view nowhere near enough proper scrutiny has been applied to company performance and the data.

So here's a question: what has the company achieved in the past 5 years? Because anybody looking at this objectively would see that the SP is pretty much at historic lows and lower than the same time 5 years ago, they would also note that there's been no meaningful regulatory success/approval and obviously no commercial revenue in 5 years- and then also study the annual reports and take note of the generous compensation and substantial pay rises awarded to certain company executives. And that person would be entitled to conclude that something doesn't compute.

Bear in mind this technology didn't start with OSL 5 years ago- it's been bumbling along since the mid-2000's originally with psivida. Anywhere else a therapy wouldn't be allowed to get this far because it would be killed off long ago rather than continue to suck in resource for a decade and a half. And all this time, even in something as tough as pancreatic cancer, things evolve and the science moves on. E.G. Check out the MRIdian data recently presented- MRI-guided external stereotactic radiotherapy - CE marked and FDA approved. Delivers a dose to pancreas not that much lower than Oncosil device with survival results it seems at least as good as if not better than OSL- and few side effects. And it seems endorsed by the American Radiation oncology society who've just released guidelines (with thanks to my rad onc mate for alerting me to that). So here's another question: why bother with a device that needs special radiation handling and giving patient GA to pop an endoscope in them and all the extra work for a hospital that that entails if there's something like the MRIdian technology? Because the rate this is going, even if BSI relents and CE mark is eventually given, the device could set some sort of record in the field of medicine as the only therapy that was rendered obsolete on day 1 of marketing!